13/09/2023 - 16:54

Chimeric gets US backing for “natural killer” cancer trial

13/09/2023 - 16:54


Save articles for future reference.

Australian med-tech Chimeric Therapeutics has secured the support of a United States cancer centre for a trial of its “natural killer” cell therapy for newly-diagnosed patients with acute myeloid leukemia. The clinical “Advent_AML” study, designed to enrol up to 20 patients at the University of Texas’ MD Anderson Cancer Center, will include a novel first-time combination with standard-of-care therapy.

Subscribe today for award-winning, unbiased and trusted journalism

Subscription Options